February 02, 2026 | Monday | News
Lupin and TB Alliance will collaborate to support the clinical development and commercialisation of Telacebec
A new partnership aims to accelerate the fight against devastating infectious diseases. Global pharmaceutical company Lupin announced a strategic collaboration with TB Alliance, a nonprofit drug developer, on February 2, 2026, to advance the clinical development and commercialization of Telacebec (formerly known as Q203). This investigational drug shows promise in treating multiple mycobacterial diseases, including tuberculosis (TB), leprosy, and buruli ulcer.
The collaboration will see Lupin and TB Alliance working together to support the drug’s progression through clinical trials and eventual availability to patients. TB Alliance will maintain leadership in the development process, while Lupin will lend its expertise in global manufacturing, navigating regulatory hurdles, and establishing a robust supply chain to ensure worldwide access to Telacebec.
A Commitment to Addressing Unmet Medical Needs
“This collaboration with TB Alliance underscores Lupin’s enduring commitment to improving patient outcomes in areas of significant unmet medical need,” said Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU, Lupin. “By leveraging our manufacturing scale and global distribution capabilities alongside TB Alliance’s deep expertise in drug development, we aim to enable timely and equitable access to Telacebec and contribute meaningfully to the global fight against tuberculosis, leprosy, and Buruli ulcer.”
Telacebec is viewed as a potential game-changer for diseases that have historically lacked effective treatments. “Telacebec represents the kind of scientific innovation that has the potential to transform treatment for diseases that have long been neglected,” said Mel Spigelman, MD, President and CEO, TB Alliance. “By partnering with Lupin, we are combining deep scientific expertise with global Chemistry, Manufacturing and Controls and access capabilities to help move this promising compound forward as quickly and responsibly as possible, with the ultimate goal of delivering better treatment options to people affected by tuberculosis, leprosy, and Buruli ulcer around the world.”
What is Telacebec? Telacebec (formerly Q203) is an investigational drug being developed for the treatment of multiple mycobacterial diseases, including tuberculosis, leprosy, and buruli ulcer.
